43.00
1.16 (2.78%)
| Penutupan Terdahulu | 41.84 |
| Buka | 41.13 |
| Jumlah Dagangan | 12,511,779 |
| Purata Dagangan (3B) | 11,411,919 |
| Modal Pasaran | 16,801,546,240 |
| Harga / Jualan (P/S) | 7.57 |
| Harga / Buku (P/B) | 1.80 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Feb 2026 |
| Margin Keuntungan | -105.67% |
| Margin Operasi (TTM) | -972.22% |
| EPS Cair (TTM) | -8.73 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -35.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.40% |
| Nisbah Semasa (MRQ) | 4.22 |
| Aliran Tunai Operasi (OCF TTM) | -3.05 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.20 B |
| Pulangan Atas Aset (ROA TTM) | -15.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Moderna, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.50 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.28% |
| % Dimiliki oleh Institusi | 73.67% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 63.00 (Piper Sandler, 46.51%) | Beli |
| Median | 26.50 (-38.37%) | |
| Rendah | 18.00 (Leerink Partners, -58.14%) | Jual |
| Purata | 30.50 (-29.07%) | |
| Jumlah | 1 Beli, 5 Pegang, 2 Jual | |
| Harga Purata @ Panggilan | 26.91 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 07 Jan 2026 | 34.00 (-20.93%) | Pegang | 35.89 |
| Jefferies | 12 Dec 2025 | 30.00 (-30.23%) | Pegang | 29.46 |
| Morgan Stanley | 12 Dec 2025 | 28.00 (-34.88%) | Pegang | 29.46 |
| Leerink Partners | 21 Nov 2025 | 18.00 (-58.14%) | Jual | 23.72 |
| Piper Sandler | 21 Nov 2025 | 63.00 (46.51%) | Beli | 23.72 |
| RBC Capital | 21 Nov 2025 | 25.00 (-41.86%) | Pegang | 23.72 |
| B of A Securities | 10 Nov 2025 | 21.00 (-51.16%) | Jual | 24.76 |
| Barclays | 07 Nov 2025 | 25.00 (-41.86%) | Pegang | 24.54 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |